Regulus UCSD Researchers Win Grant to Develop Extracellular RNA Biomarker Panel for Glioma Premium The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics. Regulus Plans for New Clinical Trials, Third Drug Candidate in '15 Premium The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year. New Data Shows Higher Dose of Regulus HCV Drug Offers Better Viral Load Reductions Premium The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments. Regulus Hits Milestone in Biogen Idec microRNA Biomarker Deal Regulus said it was able to develop its miRNA extraction and profiling technology to meet the quality specifications set out by its partner. Alnylam Publishes Paper on Development of GalNAc Conjugate Delivery Technology Premium The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms. Nov 24, 2014 Data Point to Regulus Alport Drug Use in Late-stage Disease, Other Kidney Diseases Premium Nov 6, 2014 Regulus Weighs Dual Development Track for HCV Drug Premium Nov 6, 2014 Regulus Closes $103.5M Stock Offering Premium Nov 6, 2014 Wall Street in October Proves Tumultuous for Four RNAi/microRNA Shops Premium Oct 30, 2014 Regulus to Raise $90M in Stock Offering Premium Oct 23, 2014 Regulus Stock Surges on Positive Phase I HCV Data; Phase II on Deck for 2015 Premium Sep 25, 2014 Regulus Begins Natural History of Disease Study for Alport Syndrome Premium Aug 21, 2014 IP Update: Recent Patents Awarded to Alnylam, Baxter, GE Healthcare, and More Premium Aug 7, 2014 Regulus Sets Bar High for HCV Program, Sees Alport Drug in Phase II by 2015 Premium Aug 5, 2014 Regulus, Biogen Ink New Agreement for Potential MS miRNA Biomarkers Jul 24, 2014 Regulus Study Points to Possibility of Adverse Effects with Chronic miR-33 Inhibition Premium Jul 24, 2014 Regulus Receives Orphan Drug Designation for Alport Syndrome Drug Premium Jun 26, 2014 Microlin Lowers IPO Price Range as it Continues to Seek a Public Listing Premium Jun 26, 2014 People in the News: Paul Grint, Jennifer Doudna, Emmanuelle Charpentier Premium Jun 12, 2014 Regulus Weighs Spinoff of microRNA Biomarker Unit Premium May 15, 2014 Regulus Posts Increased Q1 Losses, Lower Revenues Premium Apr 10, 2014 Regulus Preclinical Data Shows Liver Cancer Biomarker Potential of microRNAs Premium Apr 9, 2014 At AACR, Researchers Highlight Multiple Roles of microRNAs in Cancer Mar 6, 2014 Regulus Provides Details on AstraZeneca Alliance, In-house Pipeline Programs Premium Feb 20, 2014 Regulus Names Alport Syndrome as Next Pipeline Indication Premium Load More Breaking News In Brief This Week: Illumina, Personalis, Proteomedix, and More Ancient DNA Details Population Dynamics Within Andean Tiwanaku Civilization Genomic Data Spanning 2K Years Gives Glimpse of Etruscan Origins, Population Changes People in the News: New Appointments at Hologic, Akoya Biosciences, Caris Life Sciences, More At NSGC, Genetic Counselors Address Race-Based Medicine, Ways to Change New Products Posted to GenomeWeb: Becton Dickinson, Cosmos-ID, OncoDNA, More The Scan US Booster Eligibility Decision The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions. Arizona Bill Before Judge The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction. Additional Genes Wales is rolling out new genetic testing service for cancer patients, according to BBC News. Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.